Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen

Publisher： Karger

E-ISSN： 1663-2826|81|3|204-210

ISSN： 1663-2818

Source： Hormone Research in Paediatrics, Vol.81, Iss.3, 2013-12, pp. : 204-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Long-Term Effects of Switching from Active Intravenous Bisphosphonate Treatment to Low-Dose Maintenance Therapy in Children with Osteogenesis Imperfecta

By  

Hormone Research in Paediatrics, Vol. 83, Iss. 3, 2015-02 ,pp. : 183-189

Karger

Access to resources Recommend Favorite

Intravenous Pamidronate Treatment Improves Growth in Prepubertal Osteogenesis Imperfecta Patients

By  

Hormone Research in Paediatrics, Vol. 75, Iss. 5, 2011-02 ,pp. : 354-361

Karger

Access to resources Recommend Favorite

Reshaping of Vertebrae during Treatment with Neridronate or Pamidronate in Children with Osteogenesis Imperfecta

By  

Hormone Research in Paediatrics, Vol. 76, Iss. 5, 2011-09 ,pp. : 321-327

Karger

Access to resources Recommend Favorite

Recombinant versus Urinary Follicle-Stimulating Hormone in the Low-Dose Regimen in Anovulatory Patients with Polycystic Ovary Syndrome: A Safer and More Effective Treatment

By  

Hormone Research in Paediatrics, Vol. 55, Iss. 5, 2001-12 ,pp. : 224-228

Karger

Access to resources Recommend Favorite

Intravenous Pamidronate Treatment in Children with Moderate-to-Severe Osteogenesis Imperfecta Started under Three Years of Age

By  

Hormone Research in Paediatrics, Vol. 79, Iss. 6, 2013-05 ,pp. : 333-340

Karger

Access to resources Recommend Favorite